用于测量肌萎缩侧索硬化疾病进展的Rasch构建的肌萎缩侧索硬化损害多域量表的开发
研究基于荷兰ALS注册库367例患者每两月一次、为期12个月的在线问卷数据,通过因子分析与Rasch分析构建包含延髓7项、运动11项、呼吸5项三个单维度子量表的AIMS。子量表重测信度0.91-0.94,与生存强相关(p<0.001);相比ALSFRS-R,6个月和12个月临床试验所需样本量分别减少16.3%和25.9%。
要点
- 子量表满足Rasch模型要求,重测信度0.91-0.94,与生存强相关(p<0.001)。
- 相比ALSFRS-R,AIMS使6个月和12个月试验样本量分别减少16.3%和25.9%。
核心结论
- 研究开发的AIMS包含延髓、运动、呼吸三个单维度子量表,可能比总分更好地刻画疾病严重程度。
- AIMS子量表重测信度高、针对疾病进展测量进行优化,且与生存时间强相关。
- AIMS易于实施,可能提高ALS临床试验识别有效治疗的可能性。
研究设计与样本
- 荷兰ALS注册库患者在线完成ALSFRS-R及基于文献回顾和患者意见的初步问卷,每两月一次,为期12个月。
- 进行2周重测、因子分析、Rasch分析和信噪比优化策略以构建多域量表。
- 评估信度、纵向下降及与生存的关联,并评估以ALSFRS-R或AIMS子量表为主要终点族时检测进展率降低35%所需样本量。
主要发现
- 包含110个问题的初步问卷由367例患者完成。
- 识别出三个单维度子量表,构建的多域量表包含延髓7项、运动11项、呼吸5项问题。
- 子量表满足Rasch模型要求,重测信度0.91-0.94,与生存强相关(p<0.001)。
- 相比ALSFRS-R,AIMS的信噪比更高,因患者在各子量表上下降更均匀。
- 相比ALSFRS-R,AIMS在6个月和12个月临床试验中估计样本量分别减少16.3%和25.9%。
关键数值与推荐
- AIMS包含延髓7项、运动11项、呼吸5项问题,共三个单维度子量表。
- 子量表重测信度0.91-0.94,与生存关联p<0.001。
- 相比ALSFRS-R,AIMS使6个月临床试验样本量减少16.3%、12个月减少25.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Current scales used in amyotrophic lateral sclerosis (ALS) attempt to summarize different functional domains or "dimensions" into 1 overall score, which may not accurately characterize the individual patient's disease severity or prognosis. The use of composite score risks declaring treatments ineffective if not all dimensions of ALS disease progression are affected equally. We aimed to develop the ALS Impairment Multidomain Scale (AIMS) to comprehensively characterize disease progression and increase the likelihood of identifying effective treatments. METHODS: The Revised ALS Functional Rating Scale (ALSFRS-R) and a preliminary questionnaire, based on literature review and patient input, were completed online by patients from the Netherlands ALS registry at bimonthly intervals over a period of 12 months. A 2-week test-retest, factor analysis, Rasch analysis, and a signal-to-noise optimization strategy were performed to create a multidomain scale. Reliability, longitudinal decline, and associations with survival were evaluated. The sample size required to detect a 35% reduction in progression rate over 6 or 12 months was assessed for a clinical trial that defines the ALSFRS-R or AIMS subscales as a primary endpoint family. RESULTS: The preliminary questionnaire, consisting of 110 questions, was completed by 367 patients. Three unidimensional subscales were identified, and a multidomain scale was constructed with 7 bulbar, 11 motor, and 5 respiratory questions. Subscales fulfilled Rasch model requirements, with excellent test-retest reliability of 0.91-0.94 and a strong relationship with survival (p < 0.001). Compared with the ALSFRS-R, signal-to-noise ratios were higher as patients declined more uniformly per subscale. Consequently, the estimated sample size reductions achieved with the AIMS compared with those achieved with the ALSFRS-R were 16.3% and 25.9% for 6-month and 12-month clinical trials, respectively. DISCUSSION: We developed the AIMS, consisting of unidimensional bulbar, motor, and respiratory subscales, which may characterize disease severity better than a total score. AIMS subscales have high test-retest reliability, are optimized to measure disease progression, and are strongly related to survival time. The AIMS can be easily administered and may increase the likelihood of identifying effective treatments in ALS clinical trials.
引用
- de Jongh AD, van Eijk RPA, Bakker LA, et al. Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALS. Neurology. 2023. PMID: 37311649. doi:10.1212/WNL.0000000000207483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。